Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12091392-B2

Patent

Publication Date

2024-09-17

Expiration Date


Abstract

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

Core Innovation

The disclosure relates to small-molecule therapeutic agents that modulate eukaryotic initiation factor 2B (eIF2B), including the use of eIF2B modulators for treatment and prevention of integrated stress response (ISR)-mediated diseases. The described therapeutic focus includes neurodegenerative disorders and cancer, and the disclosure ties the activity to ISR biology involving ATF4 and stress granules.

The invention defines compounds of Formula I, Formula IIA-IIM, and Formula IIB with a core heterocycle/aromatic framework and a bicyclic ring A. Ring A includes bicyclo[1.1.1]pentane or bicyclo[2.1.1]hexane, while ring B is defined through Q1 and Q2, with Q1 selected as O or NR15 and Q2 defined as O.

Ring-linker and substitution patterns are described using a linker L, ethylene optionally substituted with one to three halo, and multiple substituent variables including R2, R6-R8, R11-R12, R15, R20/R21, and R30/R31 with optional formation of heterocyclyl. The disclosure also covers pharmaceutically acceptable salts, isotopically enriched analogs including deuterated analogs, stereoisomers and mixtures of stereoisomers, prodrugs, pharmaceutical compositions, and therapeutic administration using an effective amount of the compounds.

Claims Coverage

The provided independent claims cover a Formula IIB compound and a method of preparing that Formula IIB compound, including salt, isotopically enriched analog, stereoisomer, or mixture of stereoisomers. The inventive scope centers on a constrained eIF2B-modulator scaffold with bicyclic ring A, Q1/Q2-defined ring B, and an ethylene linker, together with a multi-stage preparation framework through Formula 2 and optional nitrogen deprotection.

Formula IIB compound scaffold with bicyclo[1.1.1]pentane ring A and Q1/Q2-defined ring B

A compound of Formula IIB, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein ring A is bicyclo[1.1.1]pentane; ring B has Q1 is O or NR15 and Q2 is O; and L is ethylene optionally substituted with one to three halo, with additional substituent constraints defining R2, R6/R7/R8, R11, R12, R15, R20/R21, and R30/R31 including optional heterocyclyl formation.

Preparation of Formula IIB compounds via contacting Formula 1 with H-Q1-L-Q2-R2 and optional deprotection to yield Formula IIB

A method of preparing a compound of Formula IIB, or a salt, isotopically enriched analog, stereoisomer, or mixture of stereoisomers thereof, comprising contacting a compound of Formula 1, where R100 is halo and R101 is the moiety or a nitrogen protecting group, with a compound of Formula H-Q1-L-Q2-R2 under conditions suitable to provide a compound of Formula 2; when R101 is the moiety the method provides the Formula IIB compound, and when R101 is a nitrogen protecting group the method further comprises removing the nitrogen protecting group and contacting the compound of Formula 2 with a compound of Formula 3, where LG is a leaving group, under conditions suitable to provide the Formula IIB compound.

The claims define a Formula IIB chemical space by fixing ring A to bicyclo[1.1.1]pentane, defining ring B with Q1 and Q2 as specified, and constraining the ethylene linker L and multiple substitution variables. A separate independent claim covers preparing these compounds through a Formula 2 intermediate, with optional nitrogen deprotection and subsequent Formula 3 coupling.

Stated Advantages

The compounds modulate eIF2B and are used for treatment and prevention of integrated stress response-mediated diseases.

Documented Applications

Treatment and prevention of ISR-mediated diseases, notably neurodegenerative disorders including Alzheimer’s, Parkinson’s, ALS, frontotemporal dementia, prion disease, and cancer.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.